UCB (OTCMKTS:UCBJF) Downgraded to “Underperform” at Credit Suisse Group

Credit Suisse Group cut shares of UCB (OTCMKTS:UCBJFGet Rating) from a neutral rating to an underperform rating in a research report report published on Thursday, The Fly reports.

UCBJF has been the topic of a number of other research reports. Jefferies Financial Group cut shares of UCB from a buy rating to a hold rating in a research note on Monday, July 25th. Morgan Stanley reduced their price objective on shares of UCB from €110.00 ($112.24) to €105.00 ($107.14) in a report on Friday, July 15th. JPMorgan Chase & Co. downgraded UCB from an overweight rating to a neutral rating and set a $120.00 target price for the company. in a research report on Thursday, July 14th. Berenberg Bank dropped their target price on UCB from €120.00 ($122.45) to €111.00 ($113.27) and set a buy rating for the company in a research report on Friday, July 15th. Finally, Citigroup downgraded UCB from a neutral rating to a sell rating in a research report on Thursday, July 7th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of Hold and an average target price of $105.25.

UCB Price Performance

Shares of UCB stock opened at $73.25 on Thursday. The company has a quick ratio of 1.00, a current ratio of 1.31 and a debt-to-equity ratio of 0.25. The company has a 50 day moving average price of $77.93 and a 200 day moving average price of $95.58. UCB has a 52 week low of $68.96 and a 52 week high of $122.90.

About UCB

(Get Rating)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

Featured Stories

The Fly logo

Analyst Recommendations for UCB (OTCMKTS:UCBJF)

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.